FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to agents for combined treatment of patients with cancer. Disclosed is a method of treating cancer by administering an effective amount of HQP-1351, where HQP-1351 has the following structure:
or a pharmaceutically acceptable salt thereof and asciminib. Also disclosed are a method of inhibiting mutants BCR-ABL, a method of treating non-small cell lung cancer.
EFFECT: group of inventions provides effective methods of therapy and means of treating cancer.
20 cl, 16 dwg, 6 tbl, 3 ex
| Title |
Year |
Author |
Number |
| IMMUNE-MODIFYING PARTICLES FOR CANCER TREATMENT |
2019 |
|
RU2794261C2 |
| COMPOSITIONS AND METHODS FOR TARGET ELIMINATION OF MUTATION ESCAPE IN TARGET CANCER THERAPY |
2008 |
- Ehjpelian Dehvid
- Frantsuzoff Aleks
- Rodell Timoti K.
|
RU2505313C2 |
| CANCER THERAPY BY COMBINED USE OF ONCOLYTIC SMALLPOX VACCINE VIRUS AND IMMUNE CONTROL POINT INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND COMBINED DRUG FOR USE IN CANCER THERAPY |
2019 |
- Nakao Shinsuke
- Kawase Tatsuya
|
RU2788874C2 |
| ANTICANCER COMPOSITION CONTAINING A RECOMBINANT ADENOVIRUS EXPRESSING A DESTRUCTIVE FACTOR FOR AN EXTRACELLULAR MATRIX |
2017 |
|
RU2742726C2 |
| METHODS OF TREATING CORONAVIRUS INFECTIONS |
2021 |
- Zhai, Yifan
- Yang, Dajun
- Fang, Douglas Dong
- Zhu, Hengrui
|
RU2825648C1 |
| ANTICANCER THERAPY USING COMPOUNDS OF 3,5-DISUBSTITUTED BENZENE ALKYNYL AND PEMBROLIZUMAB |
2020 |
- Yonekura, Kazuhiko
- Hirai, Hiroshi
- Matsuoka, Kazuaki
|
RU2822064C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS |
2006 |
- Nagle Advait
- Grej Natanael Shiander
- I Lju
- Rehn' Pinda
- Sim Taehbo
- Ju Shuli
|
RU2411242C2 |
| METHODS OF TREATING CANCER USING ACTIVATED T-CELLS |
2016 |
- Tang, Longqing
- Tao, Ran
- Liu, Junyun
- Wu, Dongyun
- Han, Yanyan
- Li, Jin
- Zhou, Xiangjun
|
RU2729362C2 |
| ANTICANCER COMPOSITION CONTAINING A TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND AN IMMUNE RESPONSE CONTROL POINT INHIBITOR |
2018 |
|
RU2740713C1 |
| ANTICANCER COMPOSITION CONTAINING TUMOR-SPECIFIC ONCOLYTIC ADENO VIRUS AND INHIBITOR OF CONTROL POINT OF IMMUNE RESPONSE |
2018 |
|
RU2777523C2 |
